Ride a bike
8 ClinicalTrials.gov REDEFINE 3 (NCT05669755)Ongoing cardiovascular-outcomes (MACE) trial of CagriSema in obesity with established cardiovascular disease
The honest framing is this: across incretin weight-loss drugs, roughly 25-40% of total weight lost is lean mass and the remaining 60-75% is fat
For that article we spoke with Albert Li, medical and surgical retina specialist and Clinical Assistant Professor of Ophthalmology at Zucker School of Medicine at Hofstra/Northwell, who had presented data at ARVO indicating that Ozempic was associated with higher rates of DR, as well as other adverse ocular events, when compared to other glucagon-like peptide 1 (GLP-1) receptor agonists, such as Tanzeum, Trulicity, and Victoza
The most common issues include nausea, vomiting, diarrhea, or constipation
Direct chronotropic and inotropic effects of mildronate using cross-circulated dog atrial and ventricular preparations